Sector News

J&J adds 200 jobs with new biopharma plant at site in Ireland

October 8, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Johnson & Johnson’s Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility and added 200 jobs.

The official opening, which was announced by IDA Ireland, boosted the site’s size by 19,100 square meters (205,590 square feet).

“Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions …” Kathy Wengel, J&J’s chief global supply chain officer, said in a statement.

The company started on the €300 million project in 2017. The additions included expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes.

At the time the company said the new plant would bolster capacity of APIs for drugs that treat “multiple myeloma, rheumatoid arthritis and Crohn’s disease.” While it didn’t specifically identify the products to be made there, J&J sells blockbuster Remicade for rheumatoid arthritis and Crohn’s disease, as well as Simponi for treating rheumatoid arthritis and Stelara for treating Crohn’s disease.

According to a new forecast from GlobalData, Stelara is expected to be the ninth-best selling drug globally in 2025 with $7.5 billion in sales.

By Eric Palmer

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

October 18, 2019

Trial blazers

Life sciences

LinkedIn Twitter FacebookAmid the chaos of Brexit, pioneering clinical research continues defiantly, plotting its way through the complexity of disease and providing patients with the currencies of hope, transformation and […]

October 17, 2019

Sanofi aims to save 1,100 jobs in Bangladesh by selling its local stake: report

Life sciences

LinkedIn Twitter FacebookSanofi has been weighing strategic options in Bangladesh for several weeks, and now it’s decided to leave the country, an executive told reporters. The drugmaker’s local managing director […]

October 16, 2019

Alexion fortifies rare blood disorder drugs business with Achillion deal

Life sciences

LinkedIn Twitter FacebookAlexion Pharmaceuticals Inc on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc in a deal initially valued at $930 million, as the company looks to retain its […]

Subscribe to our Weekly Newsletter

We're easy to reach